Bayer HealthCare has announced that it will be showcasing the data its procured from its oncology franchise portfolio at the 2015 European Cancer Congress (ECC2015) on Sept. 25-29 in Vienna.
“Building on the clinical success of our approved oncology portfolio, we continue to prioritize the treatment development programs that show promise for combating the toughest cancers with high unmet medical needs,” Bayer's HealthCare Executive Committee member and head of Global Development Joerg Moeller said. “The research Bayer is presenting at ECC2015 represents our ongoing commitment to advancing our understanding of therapeutic options for cancer patients worldwide.”
The data in specific that will be showcased is analysis Bayer Healthcare conducted regarding its CONSIGN and CONCUR trials of Stivarga (regorafenib) tablet in previously treated metastatic colorectal cancer (mCRC) patients. Findings from Bayer Healthcare’s Phase III ALSYMPCA trials and its U.S. expanded access program (EAP) of Xofigo (radium Ra 223 dichloride) injection in patients with metastatic castration-resistant Prostate cancer (mCRPC), symptomatic bone metastases and no known visceral metastatic disease will also be shown as well.
Last but not least, early clinical findings on roniciclib (BAY-1000394), a cyclin-dependent kinase (CDK) inhibitor currently in Phase II clinical development as a first-line therapy in combination with chemotherapy for extensive disease small cell lung cancer (ED-SCLC) will also be shown.
